In addition to these investigations using anti-PD-1 antibodies, the efficacy and safety of PD-L1 antibodies (e.g., durvalumab, atezolizumab, and avelumab) have also been evaluated in GBM patients, with results showing potential antitumor efficacy and favorable tolerability [38–41]. This evidence concerns the gene CD274 and glioblastoma.